FDA Investigator Anthony C Warchut

Anthony C Warchut has inspections in 7 countries as of 22 Sep 2023. Anthony C Warchut has collaborated with a combinined 4108 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
145
Last Inspection Date:
22 Sep 2023
Investigator Role:
FDA Investigator
Redica ID:
100002556
Country:
United States of America, Austria, Canada, Italy, France, United Kingdom of Great Britain and Northern Ireland, Germany
Co-Investigator(s):
Abdur Rafay Shareef, Abthony C Warchut, Adetutu M Gidado, Alice C Silva, Alicia M Mozzachio, Amber G Wardwell, Amy C Jordan, Anastasia M Shields, Andrew M Barlow, Anissa M Cheung, Anna Lazar, Anna M Brannen, Anthony A Charity, Anthony C Warcnut, Anthony C Warren, Anthony N Onianwa, Arie C Menachem, Arthur T Ogdahl, Azza Talaat, Brandy N Lepage, Brenda P King, Brenna L Macdowell, Brentley S Collins, Brian D Nicholson, Bryan L Mcguckin, Burnell M Henry, Byungja E Marciante, Carl A Huffman, III, Carr, Cassandra L Abellard, Charles M Edwards, Charles R Cote, RIC, Christina Capacci Daniel, PhD, Christine M Smith, Christopher Janik, Chunsheng Cai, PhD, Constance Desimone, Courtney N Long, Cynthia A Palmer, Cynthia F Kleppinger, MD, Cynthia J Lee, MS, Cynthia Jim, CSO, Daniel L Zheng, Darin S Wiegers, Daryl A Dewoskin, David P Vanhouten, David Van Houten, Deborah A Greco, Deborah M Trout, Demitria J Xiradakis, Diane C Thibodeau, Diane M Prince, Dien N Nguyen, Dina K West, Doan T Nguyen, PharmD, Dominic R Frasca, Donald C Obenhuber, PhD, Donald L Lech, Douglas Florentino, Dr. Robert C Horan, MD, Dr. Sriram Subramaniam, PhD, Edmund F Mrak, Jr, Eduardo L Rodriguez, Edward J Janik, Ekaterina Allen, Elizabeth Ll Edwards, Ellen P Madigan, Emily J Orban, Emily J Schramm, Eric M Mueller, PharmD, Erik W Koester, Erika V Butler, Erin D Mccaffery, Erin I Keith, Frederick Razzaghi, Gabrielle J Swain, Gale E Ryan, Gam S Zamil, Gary J Hagan, George J Flynn, Geraldine D Sanders, Gerard D Difiore, Hang N Guo, Heika R Tait, Helen B Ricalde, Holly Brevig, James C Maclaughlin, Janete F Guardia, Javier O Vega, Jawaid Hamid, Jayaleka J Amarasinghe, Jeffrey A Sommers, Jeffrey J Thibodeau, John A Hollings, John J Thibodeau, John P Mistler, Jonah S Ufferfilge, Jonathan G Matrisciano, Jorge L Guadalupe, Jose Acruz Gonzalez, Jose Alopez Rubet, Jose R Hernandez, Junho Pak, Justin A Boyd, Justine M Corson, Justine Tomasso, Katherine D Adams, Katherine Szestypalow, Katie L Korchinski, Kelly R Lewis, Kenneth H Williams, Kent A Conforti, Kham Phommachanh, Kimberly M White, Larry K Austin, Laura L Staples, Laurie A Haxel, Laurie B Frazier, LCDR Debra Emerson, Libia M Lugo, Linda L Green, Lori A Holmquist, LT Tamara J Henderson, Luis A Dasta, Lynda L Perry, PhD, M Patriciaurphy Murphy, Margaret A Smithers, Margaret E Walsh, Margaret M Annes, Margaret M Sands, Marianela Aponte Cruz, Marie A Fadden, Marie F Morin, Mark A Heard, Mark C Lookabaugh, Mark R Mcclain, Martin J Guardia, Marvin D Jones, Mary Jeanet Mcgarry, Maryam Tabatabaie, Matthew C Watson, Maya M Davis, Megan A Haggerty, Mei Chiung J Huang, Meisha A Mandal, Melinda L Rice, Miah Jung, Michael F Skelly, PhD, Michael G Mayfield, Michael J Sevka, MD, Michael L Chasey, Michele L Obert, Michelle M Noe, Michelle M Noe Varga, Miguel A Martinez, Mra Davism, Mra M Barbosar, Mra Mcculloughj, Nabil Nakhoul, Nadeem I Chaudhry, Nealie C Newberger, Nebil A Oumer, Nicole E Knowlton, Nina Yang, Omotunde O Osunsanmi, Paraluman S Leonin, Parul M Patel, Paul E Stein, Paul L Bellamy, Peter R Lenahan, Phillip E Mclaughlin, Raeann R Wu, Rajiv R Srivastava, Ramon E Martinez, Rapti D Madurawe, Reba A Gates, Rebecca B Welch, Rebecca E Dombrowski, Rebecca Parrilla, Robert J Martin, Robin Levis, PhD, Rory K Geyer, Rose M Ashley, Rose Xu, Rozelle G Smith, Russell J Glapion, Saied A Asbagh, Saleem A Akhtar, Sam Pepe, Samina S Khan, Samir C Gala, Samuel T Walker, Sandra A Hughes, Sara M Onyango, Satheesh Thomas, Sean R Marcsisin, Sharon K Gershon, Sharon K Thoma, PharmD, Shirley J Berryman, Simone E Pitts, Sneha S Patel, Sony Mathews, Stacey S Degarmo, Stacie A Woods, State Agency, Stephanie A Slater, MS, Stephanie Mangigian, MS/OSH, RN, Stephen R Souza, Sunita Pandey, Susan M Jackson, Susanna E Ford, Analyst, Susanne M Richardson, MSc RAC ELS, Suzanne M Healy, Tamil Arasu, PhD, Tanya R Syffrard, Todd D Alspach, Tonya R Johnson, Torrance J Slayton, Towanda L Terrell, Truong Xuan Nguyen (Andy), Valentino Fiorella, Victoria M Daddeo, Wayne T Smith, Xiaokuang Lai, PhD, Yumi J Hiramine, Yvins Dezan, Zachary L Stamm, Zakaria I Ganiyu, Zhongren Wu

Anthony C Warchut's Documents

Publish Date Document Type Title
April, 2000 EIR Fine Organics Limited - EIR, 2000-04-04
February, 2003 FDA 483 Industria Chimica Milanese - Form 483, 2003-02-27
March, 2001 FDA 483 Intervet Production S.A. - Form 483, 2001-03-15
February, 2004 EIR Pfizer Inc. Groton Laboratories - EIR, 2004-02-04
March, 2002 EIR Patheon Austria GmbH & CoKG - EIR, 2002-05-02
March, 2002 FDA 483 Response AbbVie Deutschland GmbH & Co KG - Form 483R, 2002-04-02
February, 2003 EIR SICOR Societa' Italiana Corticosteroidi s.r.l. - EIR, 2003-03-19
February, 2003 EIR Corden Pharma Bergamo SpA - EIR, 2003-05-16
May, 2003 EIR Pfizer Inc. Groton Laboratories - EIR, 2003-05-01
February, 2003 EIR Trifarma S.p.A. - EIR, 2003-02-27
January, 2001 FDA 483 Boehringer Ingelheim Pharmaceuticals, Inc. - Form 483, 2001-01-16
December, 2003 FDA 483 Response R.S.A. Corp. - Form 483R, 2004-01-05
March, 2002 FDA 483 Response Patheon Austria GmbH & CoKG - Form 483R, 2002-03-27
February, 2005 EIR Boehringer Ingelheim Pharmaceuticals, Inc. - EIR, 2005-02-24
February, 2003 FDA 483 Response SICOR Societa' Italiana Corticosteroidi s.r.l. - Form 483R, 2003-04-03
March, 2004 EIR SICOR Societa' Italiana Corticosteroidi s.r.l. - EIR, 2004-04-14
January, 2001 EIR Purdue Pharma L.P. - EIR, 2001-01-02
May, 2006 FDA 483 Curia Massachusetts, Inc. - Form 483, 2006-05-24
December, 2003 FDA 483 R.S.A. Corp. - Form 483, 2003-12-10
December, 2003 EIR R.S.A. Corp. - EIR, 2003-12-10
December, 2001 EIR Purdue Pharma, L.P. - EIR, 2001-12-18
August, 2000 FDA 483 Pfizer Global Research & Development, Pfizer Inc. - Form 483, 2000-08-10
July, 2001 EIR Lincare Inc. - EIR, 2001-07-03
August, 2002 EIR Ecometics, Inc. - EIR, 2002-08-08
August, 2001 EIR Paul R. Solomon, Ph.D. - EIR, 2001-08-03
January, 2005 FDA 483 Charles River Laboratories Preclinical Services - Form 483, 2005-01-27
July, 2001 EIR Bayer HealthCare Pharmaceuticals Inc - EIR, 2001-07-23
October, 2005 FDA 483 Sheffield Pharmaceuticals LLC - Form 483, 2005-10-19
May, 2000 FDA 483 Jeffrey Breiter, Md - Form 483, 2000-05-17
October, 2002 FDA 483 Sheffield Pharmaceuticals LLC - Form 483, 2002-10-03
February, 2003 FDA 483 Corden Pharma Bergamo SpA - Form 483, 2003-02-14
January, 2001 EIR Boehringer Ingelheim Pharmaceuticals, Inc. - EIR, 2001-01-16
February, 2001 EIR Pfizer Inc. Groton Laboratories - EIR, 2001-02-28
April, 2000 FDA 483 FINE ORGANICS, DIV. LAPORTE FINE CHEMICAL - Form 483, 2000-04-04
May, 2000 EIR Jeffrey Breiter, Md - EIR, 2000-05-17
March, 2002 EIR AbbVie Deutschland GmbH & Co KG - EIR, 2002-03-14
August, 2000 EIR Pfizer Global Research & Development, Pfizer Inc. - EIR, 2000-08-10
May, 2002 EIR Selwyn A. Cohen, M.D., Clinical Investigator - EIR, 2002-05-09
January, 2005 EIR Charles River Laboratories Preclinical Services - EIR, 2005-01-27
May, 2000 FDA 483 Bayer HealthCare Pharmaceuticals Inc - Form 483, 2000-05-04
January, 2000 EIR Michael Spiegel, MD - EIR, 2000-01-14
June, 2003 EIR Boehringer Ingelheim Pharmaceuticals, Inc. - EIR, 2003-06-09
February, 2003 FDA 483 TEVA PHARMACEUTICAL FINE CHEMICALS SRL. - Form 483, 2003-02-24
March, 2004 EIR Chemi SpA - EIR, 2004-05-04
April, 2000 FDA 483 Response Fine Organics Limited - Form 483R, 2000-05-02
January, 2003 EIR Pfizer Laboratories Div Pfizer Inc - EIR, 2003-01-23
August, 2002 FDA 483 Ecometics, Inc. - Form 483, 2002-08-08
March, 2002 FDA 483 Abbot Gmbh & Co. KG - Form 483, 2002-03-14
November, 2001 EIR Pfizer Inc. Groton Laboratories - EIR, 2001-11-29

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more